tbuckley/cabot-search huggingface dataset:
Ambulatory Blood Pressure and Mortality
Authors: Lutgarde Thijs, Wen-Yi Yang, Jan A Staessen
Journal: New England Journal of Medicine (2018)

The authors reply: Yusufov and colleagues suggest that we should have tested a brief, complex, psychologically focused intervention to mitigate surrogates' psychological distress.Although we agree that this type of intervention should be developed and tested in the ICU setting to reduce surrogates' psychological distress, we chose a broader focus for the PARTNER intervention because our intention was to improve two different domains of outcomes: surrogates' long-term psychological outcomes and the quality of decisions made for incapacitated, critically ill patients.On the basis of the available evidence when we designed the trial, 1 we hypothesized that we could improve both outcome domains with one intervention focused on improving communication and decision support.Although the PARTNER intervention improved measures of decision quality and decreased the duration of intensive treatment among dying patients, our results suggest that a different kind of intervention may be needed to improve surrogates' long-term psychological outcomes.Akca characterizes the PARTNER intervention as largely composed of scheduled interdisciplinary family meetings.We respectfully disagree with this description of the intervention, because it fails to recognize that this was a complex behavioral intervention that included extensive daily encounters between the PARTNER nurses and surrogates, not just interdisciplinary family meetings.Akca raises the question of whether the
From a Website to a National and Regional Reference Centre Network: the French Experience for Rare Ovarian Tumors
Authors: I. Ray-Coquard, P. Pautier, J. Alexandre, M. Vacher-Lavenu, M. Fabbro, A. Floquet, F. Selle, G. Ferron, N. Chiannilkulchai, E. Pujade-Lauraine
Journal: Annals of Oncology (2012)
Determining the Optimal Adjuvant Therapy for Improving Survival in Elderly Patients with Glioblastoma: A Systematic Review and Network Meta-analysis
Authors: Farshad Nassiri, Shervin Taslimi, Justin Z. Wang, Jetan H. Badhiwala, Tatyana Dalcourt, Nazanin Ijad, Neda Pirouzmand, Saleh Almenawer, Roger Stupp, Gelareh Zadeh
Journal: Clinical Cancer Research (2020)

Abstract Purpose: Older patients with glioblastoma (GBM) are underrepresented in clinical trials. Several abbreviated and standard chemoradiotherapy regimens are advocated with no consensus on the optimal approach. Our objective was to quantitatively evaluate which of these regimens would provide the most favorable survival outcomes in older patients with GBM using a network meta-analysis. Experimental Design: MEDLINE, Embase, Google Scholar, and the Cochrane Library were searched. Patients &amp;gt;60 years of age with histologically confirmed GBM were included. Primary outcome of interest was the pooled HR from randomized controlled trials (RCTs). Secondary outcomes of interest included pooled HR from studies controlling for MGMT promoter methylation status, and safety. Results: Fourteen studies, including 5 RCTs, reporting 4,561 patients were included. Using highest quality data from RCTs, our network-based approach demonstrated that standard radiotherapy (SRT) and temozolomide (TMZ) provided similar survival benefit when compared with hypofractionated radiotherapy (HRT) and TMZ [HR = 0.90; 95% confidence interval (CI), 0.43–1.87], TMZ alone (HR 1.25; 95% CI, 0.69–2.26), HRT alone (HR = 1.34; 95% CI, 0.73–2.45), or SRT alone (HR = 1.43; 95% CI, 0.87–2.36). HRT-TMZ had the highest probability (85%) of improving survival in older patients with GBM followed by SRT-TMZ (72%). Pooled analysis of trials controlling for MGMT promoter methylation status demonstrated that TMZ monotherapy confers similar survival benefit to combined chemoradiotherapy. Conclusions: Statistical comparisons using a network approach demonstrates that the common treatment regimens for older patients with GBM in previous RCTs confer similar survival benefits. Adjustments for MGMT promoter methylation status demonstrated that radiotherapy alone was inferior to TMZ-based approaches. Head-to-head comparison of TMZ monotherapy to combined TMZ and radiation is warranted.
A Retrospective Study of the Factors Tended to Transfer to Palliative Home Care from Palliative Care Unit at A Comprehensive Cancer Center in Japan
Authors: T. Miura, Y. Matsumoto, A. Okizaki, M. Oishi, S. Motonaga, Y. Higashi, A. Sekimoto, K. Abe, M. Fukui, H. Kinoshita
Journal: Annals of Oncology (2012)
Early Tumor Shrinkage (ETS) For the Prediction of Efficacy in Metastatic Colorectal Cancer (MCRC): Post-Hoc Analysis from an Irinotecan-Based Randomized First-Line Trial
Authors: C. Giessen, R. Laubender, S. Stintzing, L. Fischer von Weikersthal, D. Quietzsch, U. Vehling-Kaiser, D. Oruzio, H. Lambertz, A. Schalhorn, V. Heinemann
Journal: Annals of Oncology (2012)
Efficacy of Deep Brain Stimulation of the Ventral Anterior Limb of the Internal Capsule for Refractory Obsessive-Compulsive Disorder: A Clinical Cohort of 70 Patients
Authors: Damiaan Denys, Ilse Graat, Roel Mocking, Pelle de Koning, Nienke Vulink, Martijn Figee, Pieter Ooms, Mariska Mantione, Pepijn van den Munckhof, Rick Schuurman
Journal: American Journal of Psychiatry (2020)

Deep brain stimulation (DBS) is an effective treatment option for patients with refractory obsessive-compulsive disorder (OCD). However, clinical experience with DBS for OCD remains limited. The authors examined the tolerability and effectiveness of DBS in an open study of patients with refractory OCD.Seventy consecutive patients, including 16 patients from a previous trial, received bilateral DBS of the ventral anterior limb of the internal capsule (vALIC) between April 2005 and October 2017 and were followed for 12 months. Primary effectiveness was assessed by the change in scores on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) from baseline until the 12-month follow-up. Response was defined by a ≥35% decrease in Y-BOCS score, partial response was defined by a 25%-34% decrease, and nonresponse was defined by a <25% decrease. Secondary effectiveness measures were the Hamilton Anxiety Rating Scale (HAM-A) and the Hamilton Depression Rating Scale (HAM-D).Y-BOCS, HAM-A, and HAM-D scores all decreased significantly during the first 12 months of DBS. Twelve months of DBS resulted in a mean Y-BOCS score decrease of 13.5 points (SD=9.4) (40% reduction; effect size=1.5). HAM-A scores decreased by 13.4 points (SD=9.7) (55%; effect size=1.4), and HAM-D scores decreased by 11.2 points (SD=8.8) (54%; effect size=1.3). At the 12-month follow-up, 36 of the 70 patients were categorized as responders (52%), 12 patients as partial responders (17%), and 22 patients as nonresponders (31%). Adverse events included transient symptoms of hypomania, agitation, impulsivity, and sleeping disorders.These results confirm the effectiveness and safety of DBS of the vALIC for patients with treatment-refractory OCD in a regular clinical setting.
Efficacy and Safety Data from Patients with Advanced Melanoma and Brain Metastases Participating in the European Ipilimumab Expanded Access Programme (EAP) in Italy
Authors: P. Queirolo, E. Simeone, F. De Galitiis, L. Di Guardo, A.M. Di Giacomo, R. Marconcini, V. Ferraresi, F. De Rosa, M. Guida, S. Stragliotto
Journal: Annals of Oncology (2012)
NHS trust turned to mediation to calm tensions between paediatric urology consultants
Authors: Jacqui Wise
Journal: BMJ (2020)

Bosses at London’s Great Ormond Street Hospital have said that “successful mediation,” an away day, and “constructive conversations” between consultants helped to deal with a “dysfunctional relationship” between two consultant paediatric urology surgeons that had threatened patient safety.

The Great Ormond Street Hospital NHS Foundation Trust asked the Royal College of Surgeons of England to review its paediatric urology surgical service after concerns raised by staff, serious untoward incidents, and outcome data. A review team visited in May last year, and its report, dated last July, was published with the trust’s most recent board papers in November 2019.

The hospital’s paediatric urology service has around 3300 planned NHS admissions a year. It has six consultant surgeons, who the report said were widely reported to be …
Mantle Cell Lymphoma of Mucosa‐Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study
Authors: Lucia Morello, Sara Rattotti, Laura Giordano, Mats Jerkeman, Tom van Meerten, Katarzyna Krawczyk, Filipa Moita, Dario Marino, Simone Ferrero, Michał Szymczyk, Igor Aurer, Tarec Christoffer El‐Galaly, Alice Di Rocco, Carlo Visco, Giuseppe Carli, Irene Defrancesco, Carmelo Carlo‐Stella, Martin Dreyling, Armando Santoro, Luca Arcaini
Journal: HemaSphere (2019)

While classical nodal mantle cell lymphoma (cMCL) is often associated with involvement of multiple extranodal sites, isolated extranodal disease (ED) at the time of diagnosis is a rare event; data on the outcome of these forms are lacking. On behalf of the European MCL Network, we conducted a retrospective analysis on the clinical characteristics and outcomes of MCL presenting with isolated or predominant ED (MALT MCL). We collected data on 127 patients with MALT MCL diagnosed from 1998 to 2015: 78 patients (61%) were male with a median age of 65 years. The involved sites include: upper airways + Waldeyer ring (40; 32%), gastrointestinal tract (32; 25%), ocular adnexa (17; 13%), oral cavity and salivary glands (17; 13%) and others (13; 1%); 7 patients showed multiple extranodal sites. The median follow-up was 80 months (range: 6-182), 5-year progression-free survival (PFS) was 45% (95% CI: 35-54) and 5-year overall survival (OS) was 71% (95% CI: 62-79). In an explorative setting, we compared MALT MCL with a group of 128 cMCL patients: MALT MCL patients showed a significantly longer PFS and OS compared with nodal cMCL; with a median PFS of 4.5 years vs 2.8 years (p = 0.001) and median OS of 9.8 years vs 6.9 years (p = 0.018), respectively. Patients with MALT MCL at diagnosis showed a more favorable prognosis and indolent course than classical nodal type. This clinical variant of MCL should be acknowledged to avoid possible over-treatment.
Synthetic Polymers Provide a Robust Substrate for Functional Neuron Culture
Authors: Yichuan Zhang, Seshasailam Venkateswaran, Gustavo A. Higuera, Suvra Nath, Guy Shpak, Jeffrey Matray, Lidy E. Fratila‐Apachitei, Amir A. Zadpoor, Steven A. Kushner, Mark Bradley, Chris I. De Zeeuw
Journal: Advanced Healthcare Materials (2020)

Abstract Substrates for neuron culture and implantation are required to be both biocompatible and display surface compositions that support cell attachment, growth, differentiation, and neural activity. Laminin, a naturally occurring extracellular matrix protein is the most widely used substrate for neuron culture and fulfills some of these requirements, however, it is expensive, unstable (compared to synthetic materials), and prone to batch‐to‐batch variation. This study uses a high‐throughput polymer screening approach to identify synthetic polymers that supports the in vitro culture of primary mouse cerebellar neurons. This allows the identification of materials that enable primary cell attachment with high viability even under “serum‐free” conditions, with materials that support both primary cells and neural progenitor cell attachment with high levels of neuronal biomarker expression, while promoting progenitor cell maturation to neurons.
Concurrent Thoracic Radiotherapy (TRT) with Either the First Cycle or the Third Cycle of Cisplatin and Etoposide Chemotherapy to Determine the Optimal Timing of TRT for Limited-Disease Small-Cell Lung Cancer
Authors: J.-M. Sun, S.-W. Kim, M.-J. Ahn, J.S. Ahn, D.H. Lee, Y.C. Ahn, H. Pyo, E.K. Choi, S.Y. Song, S.-H. Lee, C. Suh, J.S. Lee, K. Park
Journal: Annals of Oncology (2012)
Prognostic Factors and Treatment Outcomes of Patients with Uterine Leiomyosarcoma: A Retrospective Study of Anatolian Society of Medical Oncology
Authors: A. Durnali, S. Tokluog˘ lu, N. Ozdemir, M. I˙nanc, N. Alkis, N. Zengin, O.U. Sonmez, M. Kucukoner, M. Ozkan, B. Oksuzoglu
Journal: Annals of Oncology (2012)
Phase II Study Alternating Mfolfox 6 and Folfiri (FIREFOX) Plus Bevacizumab (BEV) Regimen in First-Line Treatment of Advanced Colorectal Cancer in Japanese Patients (KSCC 0801)
Authors: Y. Emi, Y. Ogata, Y. Akagi, Y. Kakeji, E. Oki, H. Saeki, M. Shimokawa, T. Touyama, H. Samura, H. Baba, S. Natsugoe, K. Shirouzu, S. Tokunaga, Y. Maehara
Journal: Annals of Oncology (2012)
Prevention of connexin-43 remodeling protects against Duchenne muscular dystrophy cardiomyopathy
Authors: Eric Himelman, Mauricio A. Lillo, Julie Nouet, J. Patrick Gonzalez, Qingshi Zhao, Lai-Hua Xie, Hong Li, Tong Liu, Xander H.T. Wehrens, Paul D. Lampe, Glenn I. Fishman, Natalia Shirokova, Jorge E. Contreras, Diego Fraidenraich
Journal: Journal of Clinical Investigation (2020)

Aberrant expression of the cardiac gap junction protein connexin-43 (Cx43) has been suggested as playing a role in the development of cardiac disease in the mdx mouse model of Duchenne muscular dystrophy (DMD); however, a mechanistic understanding of this association is lacking. Here, we identified a reduction of phosphorylation of Cx43 serines S325/S328/S330 in human and mouse DMD hearts. We hypothesized that hypophosphorylation of Cx43 serine-triplet triggers pathological Cx43 redistribution to the lateral sides of cardiomyocytes (remodeling). Therefore, we generated knockin mdx mice in which the Cx43 serine-triplet was replaced with either phospho-mimicking glutamic acids (mdxS3E) or nonphosphorylatable alanines (mdxS3A). The mdxS3E, but not mdxS3A, mice were resistant to Cx43 remodeling, with a corresponding reduction of Cx43 hemichannel activity. MdxS3E cardiomyocytes displayed improved intracellular Ca2+ signaling and a reduction of NADPH oxidase 2 (NOX2)/ROS production. Furthermore, mdxS3E mice were protected against inducible arrhythmias, related lethality, and the development of cardiomyopathy. Inhibition of microtubule polymerization by colchicine reduced both NOX2/ROS and oxidized CaMKII, increased S325/S328/S330 phosphorylation, and prevented Cx43 remodeling in mdx hearts. Together, these results demonstrate a mechanism of dystrophic Cx43 remodeling and suggest that targeting Cx43 may be a therapeutic strategy for preventing heart dysfunction and arrhythmias in DMD patients.
A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood
Authors: K. Öberg, A. Califano, J.R. Strosberg, S. Ma, U. Pape, L. Bodei, G. Kaltsas, C. Toumpanakis, J.R. Goldenring, A. Frilling, S. Paulson
Journal: Annals of Oncology (2020)
Statins Limit Coenzyme Q Synthesis and Metabolically Synergize with MEK Inhibition in Pancreatic Tumors
Authors: Thekla Cordes, Christian M. Metallo
Journal: Cancer Research (2020)

Tumors frequently increase expression of enzymes in the mevalonate biosynthesis pathway. Statins inhibit flux through this pathway, but if and how such treatments elicit a therapeutic benefit in cancer remains unclear. In this issue of Cancer Research, McGregor and colleagues perform in vivo metabolic tracing to demonstrate that mouse pancreatic ductal adenocarcinoma (PDAC) tumors and human PDAC cell lines require this pathway for coenzyme Q (CoQ) synthesis and redox homeostasis. Simvastatin treatment reduces CoQ synthesis and promotes oxidative stress and apoptosis in tumors when administered in combination with a MEK inhibitor, providing a new mechanism through which statin treatment may impact PDAC growth.See related article by McGregor et al., p. 175.
Ribonucleotide Reductase Subunit 2 (RRM2) Predicts Shorter Survival in Resected Stage I-III Non-Small Cell Lung Cancer (NSCLC) Patients
Authors: F. Grossi, G. Barletta, C. Sini, E. Rijavec, C. Genova, M.G. Dal Bello, G. Savarino, M. Truini, F. Merlo, P. Pronzato
Journal: Annals of Oncology (2012)
Overall Survival (OS) to First- and Second-Line Chemotherapy Associated with Mrna Expression of Multiple Myeloma Set (MMSET) Domain, P53-Binding Protein 1 (53bp1) and Breast Cancer Susceptibility Gene 1 (BRCA1) in advanced Gastric Cancer Patients (P)
Authors: J. Wei, B. Liu, L. Yu, Z. Zou, X. Qiang, J.J. Sánchez, C. Costa, A. Gimenez-Capitan, N. Karachaliou, R. Rosell
Journal: Annals of Oncology (2012)
Left atrial function in heart failure with preserved ejection fraction: a systematic review and meta‐analysis
Authors: Muhammad Shahzeb Khan, Muhammad Mustafa Memon, Mohammad H. Murad, Muthiah Vaduganathan, Stephen J. Greene, Michael Hall, Filippos Triposkiadis, Carolyn S.P. Lam, Amil M. Shah, Javed Butler, Sanjiv J. Shah
Journal: European Journal of Heart Failure (2020)
Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post PCI in Patients With Atrial Fibrillation
Authors: Philippe Gabriel Steg, Gregory Ducrocq, Deepak L. Bhatt, Stefan H. Hohnloser, Matias Nordaby, Corinna Miede, Gregory Y.H. Lip, Jonas Oldgren, Jurriën M. ten Berg, Christopher P. Cannon
Journal: Journal of the American College of Cardiology (2020)
Adoptive Immunotherapy with MUC1-Specific Cytotoxic T Lymphocytes and MUC1-MRNA Transfected Dendritic Cells Plus Gemcitabine for Unresectable Pancreatic Cancer
Authors: Y. Shindo, S. Hazama, Y. Inoue, Y. Maeda, M. Iida, N. Suzuki, K. Yoshimura, T. Ueno, S. Yoshino, M. Oka
Journal: Annals of Oncology (2012)
Using certain indices of fibrinolytic system for forecasting the efficiency of neoajuvant chemotherapy in ovarian cancer.
Authors: Yelena Frantsiyants, Tatiana Moiseyenko, Yekaterina Komarova, Larisa Kozlova
Journal: Journal of Clinical Oncology (2013)

e22022 Background: Using cell markers that characterize biological properties of a tumor, the relevance of treatment used can be determined for each patient, further ways of surveillance of the patients can be selected, and individual forecasts of the illness can be made. Methods: After 1 course of neoajuvant chemoterapy according to the scheme CAP, in the malign tumor tissue of 21 patients (T 3a-c N 0-1 M 0-1) , the activity of plasminogen and plasmin was determined by ELISA. Then the ratio K of plasminogen (PG) and plasmin (P) was calculated. As a blank, tumor tissue of 18 patients having ovarian cancer without chemotherapy administered has been studied. On all patients, operations in full or cytoreductive surgery were performed. Results: With efficient treatment, ratio K increased (К=1,4±0,2) relative to indices in patients without neoajuvant chemotherapy (К=0,3±0,17), while it remained the same (К=0,2±0,09) or decreased relative to initial data if there was no clinical effect, which is confirmed by further development of ovarian cancer. Conclusions: Thus, determining of plasminogen and plasmin – fibrinolytic system indices – in the tumor tissue and calculating of their ratio allows detecting the patients who have effect from treatment and good forecast and ones without effect, having bad forecast, who need aggressive ajuvant treatment. It also allows determining individual sensitivity or resistance of malign tumors in patients to certain regimens of chemotherapy. At the same time, there is an opportunity to objectify the results of specific therapy.
P-0067 Screening and Triage test for Early Detection of Gastric Cancer (STEAD-GC)
Authors: Alejandro Corvalan, Alfonso Calvo, Catterina Ferreccio, Maria Maturana, Paz Cook, Marianela Sanchez, Edmundo Aravena, Carlos Barrientos, Ricardo Estela
Journal: Annals of Oncology (2012)
Rammya Mathew: Why are doctors so unhappy?
Authors: Rammya Mathew
Journal: BMJ (2020)

I’ve always been curious as to why so few doctors recommend a career in medicine. Not only do they not recommend it but some actively discourage it.1 This will no doubt come as a surprise to those outside medicine who perceive it as a highly sought-after and prestigious professional career. So, what is it that makes us deter our friends and family from following in our footsteps?

Researching this question led me to a 2001 editorial published in The BMJ by Richard Smith, editor at the …
A Combinatorial Strategy for Targeting<i>BRAF</i>V600E-Mutant Cancers with BRAFV600E Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib)
Authors: Chandrayee Ghosh, Suresh Kumar, Yevgeniya Kushchayeva, Kelli Gaskins, Myriem Boufraqech, Darmood Wei, Sudheer Kumar Gara, Lisa Zhang, Ya-qin Zhang, Min Shen, Sanjit Mukherjee, Electron Kebebew
Journal: Clinical Cancer Research (2020)

Most aggressive thyroid cancers are commonly associated with a BRAFV600E mutation. Preclinical and clinical data in BRAFV600E cancers suggest that combined BRAF and MEK inhibitor treatment results in a response, but resistance is common. One mechanism of acquired resistance is through persistent activation of tyrosine kinase (TK) signaling by alternate pathways. We hypothesized that combination therapy with BRAF and multitargeting TK inhibitors (MTKI) might be more effective in BRAFV600E thyroid cancer than in single-agent or BRAF and MEK inhibitors.The combined drug activity was analyzed to predict any synergistic effect using high-throughput screening (HTS) of active drugs. We performed follow-up in vitro and in vivo studies to validate and determine the mechanism of action of synergistic drugs.The MTKI ponatinib and the BRAF inhibitor PLX4720 showed synergistic activity by HTS. This combination significantly inhibited proliferation, colony formation, invasion, and migration in BRAFV600E thyroid cancer cell lines and downregulated pERK/MEK and c-JUN signaling pathways, and increased apoptosis. PLX4720-resistant BRAFV600E cells became sensitized to the combination treatment, with decreased proliferation at lower PLX4720 concentrations. In an orthotopic thyroid cancer mouse model, combination therapy significantly reduced tumor growth (P < 0.05), decreased the number of metastases (P < 0.05), and increased survival (P < 0.05) compared with monotherapy and vehicle control.Combination treatment with ponatinib and PLX4720 exhibited significant synergistic anticancer activity in preclinical models of BRAFV600E thyroid cancer, in addition to overcoming PLX4720 resistance. Our results suggest this combination should be tested in clinical trials.
Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification
Authors: W. Okamoto, I. Okamoto, T. Arao, S.-i. Nishina, S. Ueda, H. Kawakami, K. Yanagihara, T. Kurata, K. Nishio, K. Nakagawa
Journal: Annals of Oncology (2012)
Archer: Dacomitinib (D; PF-00299804) Versus Erlotinib (E) for Advanced (ADV) NSCLC; A Randomized Double-Blind Phase III Study
Authors: M. Boyer, P.A Jänne, T. Mok, K. O'Byrne, L. Paz-Ares, S.S. Ramalingam, J. Liang, I. Taylor, A. Campbell, J. O'Connell, S. Letrent, S.-Y. Lee, V. Antic
Journal: Annals of Oncology (2012)
Response to Sorafenib in PDGFRA-D842V Mutated Metastatic Gastrointestinal Stromal Tumor (GIST), Supported by Biomolecular Functional Analyses
Authors: E. Fumagalli, S. Pilotti, E. Conca, R. Bertulli, M. Fiore, C. Morosi, F. Bozzi, P.G. Casali, E. Tamborini
Journal: Annals of Oncology (2012)
P-0105 Clinico-Pathological Prognostic Factors and Role of Plasmatic Vegf in Pancreas Cancer Patients
Authors: Berta Laquente, Mireia Ginestà, Silvia Vázquez, Juli Busquets, Joan Fabregat, Maria José Paules, Agnès Figueras, Martín Francisco Javier Pérez, Maica Galán, Francesc Viñals
Journal: Annals of Oncology (2012)
The Enchanttm Trial: An Open Label Multicenter Phase 2 Window Of Opportunity Study Evaluating Ganetespib (Sta-9090) Monotherapy in Women With Previously Untreated Metastatic HER2 Positive or Triple Negative Breast Cancer (TNBC)
Authors: D. Cameron, M.S. Mano, V. Vukovic, F. Teofilovici, R. Bradley, A. Awada
Journal: Annals of Oncology (2012)
A Prospective, Feasibility Study of S-1 and Carboplatin for Patients with Advanced Non Small Cell Lung Cancer (NSCLC) Concomitant with Pulmonary Fibrosis (PF)
Authors: T. Kato, T. Baba, O. Yamaguchi, M. Yoshida, T. Oda, A. Takasa, T. Enomoto, T. Shinohara, E. Hagiwara, T. Ogura
Journal: Annals of Oncology (2012)